Ciprofloxacin: Review on developments in synthetic, analytical, and medicinal aspects

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 25, Issue 4, 2010, Pages 577-589

  Sharma, Prabodh Chander ^a   Jain, Ankit ^a   Jain, Sandeep ^b   Pahwa, Rakesh ^a   Yar, Mohammad Shahar ^c  

^a KURUKSHETRA UNIVERSITY   (India)

^b GURU JAMBHESHWAR UNIVERSITY OF SCIENCE AND TECHNOLOGY   (India)

^c HAMDARD UNIVERSITY   (India)

Author keywords

Analytical; Antibacterial; Ciprofloxacin; Fluoroquinolone

Indexed keywords

1 CYCLOPROPYL 6 FLUORO 3 (5 (4 NITROPHENYL) 1,3,4 OXADIAZOL 2 YL) 7 (PIPERAZIN 1 YL)QUINOLIN 4(1H) ONE; 1 CYCLOPROPYL 6 FLUORO 7 (4 (2 (5 (METHYLTHIO)THIOPHEN 2 YL) 2 OXOETHYL)PIPERAZIN 1 YL) 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 1 CYCLOPROPYL 7 (4 (2-(2,4 DICHLOROPHENYL) 2 (METHOXYIMINO)ETHYL)PIPERAZIN 1 YL) 6 FLUORO 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 4 METHYL 7 PIPERAZINE CIPROFLOXACIN; 4,5,6,7 TETRAHYDROTHIENO[3,2 C]PYRIDINE QUINOLONE; 7 (4 (2 (5 BROMOTHIOPHEN 2 YL) 2 (HYDROXYIMINO)ETHYL)PIPERAZIN 1 YL) 1 CYCLOPROPYL 6 FLUORO 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 7 (4 (5 (4 NITROBENZYLTHIO) 1,3,4 THIADIAZOL 2 YL)PIPERAZIN 1 YL) 1 CYCLOPROPYL 6 FLUORO 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 7 (4 (5 AMINO 1,3,4 THIADIAZOLE 2 YLSULFONYL)PIPERAZIN 1 YL) 1 CYCLOPROPYL 6 FLUORO 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 7 [4 {(5 BROMO 2,3 DIOXOINDOLIN 1 YL)METHYL}PIPERAZIN 1 YL] 1 CYCLOPROPYL 6 FLUORO 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; ANTACID AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; AZLOCILLIN; BENZOTHIAZOLE; BICARBONATE; BIOFLOXCIN; C FLOX; CIFRAN; CILOQUIN; CIMETIDINE; CIPFLOX; CIPFLOXAGER; CIPLOX; CIPLOXX; CIPRO HEXAL; CIPROFLOXACIN; CIPROGEN; CIPROL; CYCLOSPORIN; DYNAFLOC; METHYLXANTHINE; ORPIC; PROBENECID; PROFLOXIN; SPEC TOPISTIN; THEOPHYLLINE; TRUOXIN; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; ACUTE SINUSITIS; AGRANULOCYTOSIS; ANAPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTHRITIS; ASEPTIC MENINGITIS; BACILLUS SUBTILIS; BONE INFECTION; BONE INJURY; CONTROLLED STUDY; CYSTITIS; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SCREENING; DRUG SYNTHESIS; DRUG TISSUE LEVEL; ESCHERICHIA COLI; GONORRHEA; HALLUCINATION; HUMAN; INFECTIOUS ARTHRITIS; INSOMNIA; JOINT INJURY; MOOD DISORDER; NAUSEA; NONHUMAN; PHOTOTOXICITY; PRIORITY JOURNAL; PROSTATITIS; PYELONEPHRITIS; RESPIRATORY TRACT INFECTION; REVIEW; SEIZURE; SEXUALLY TRANSMITTED DISEASE; SINGLE DRUG DOSE; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STENOTROPHOMONAS MALTOPHILIA; TASTE DISORDER; TREATMENT INDICATION; TYPHOID FEVER; URINARY TRACT INFECTION; VOMITING; CHEMISTRY; SYNTHESIS; TREATMENT OUTCOME;

ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; HUMANS; TREATMENT OUTCOME;

EID: 77954393125     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756360903373350     Document Type: Review

References (119)

1. Dax SL. Antibacterial Chemotherapeutic Agents. London: Blackie Academic & Professional, 1997:298-345.
2. Lee C, Ronald AR. Norfoxacin: its potential in clinical practice. Am J Med 1987;82:27-34.
3. Patrick GL. An Introduction to Medicinal Chemistry. Oxford: Oxford University Press, 2003:379-435.
4. Buck ML. Ciprofoxacin use in children: a review of recent fndings. Pediatr Pharm 1998;4:12-18.
5. Pandey SN. A Text Book of Medicinal Chemistry (Synthetic and Biochemical Approach). Bhelpur: Mahavir Press, 2003:547-585
6. Torriero AAJ, Ruiz-Diaz JJJ, Salinas E, Marchevsky EJ, Sanz MI, Raba J. Enzymatic rotating biosensor for ciprofoxacin determination. Talanta 2006;69:691-699
7. Guneysel O, Onur O, Erdede M, Dehizbasi A. Trimetoprim/sulfamethoxazole resistance in urinary tract infections. J Emerg Med 2009;36:338-341
8. Karachalios GN, Zografos G, Patrikakos V, Nassopoulou D, Kehagioglou K. Biliary tract infections treated with ciprofoxacin. Infection 2005;21:262-264
9. Abraham DJ. Burger's Medicinal Chemistry Drug Discovery. Hoboken, NJ: John Wiley & Sons, 2003:582-587
10. Appelbaum PC, Hunter PA. Te fuoroquinolone antibacterials: past, present and future perspectives. Int J Antimicrob Agents 2000;16:5-15. (Pubitemid 30665419)
11. De Almeida MV, Saraiva MF, De Souza MVN, Da Costa CF, Vincente FRC, Lourenco MCS. Synthesis and antitubercular activity of lipophilic moxifoxacin and gatifoxacin derivatives. Bioorg Med Chem Lett 2007;17:5661-5664 (Pubitemid 47391305)
12. Cooper JG, Harboe K, Frost SK, Skadberg O. Ciprofoxacin interacts with thyroid replacement therapy. BMJ 2005;330:1002. (Pubitemid 40604284)
13. Ciprofoxacin. http://en.wikipedia.org/w/index.php?title= Ciprofoxacin&oldid=287777716. Accessed 6 May 2009
14. Cipro. Bayer response 12 Feb 2009. http://www.fda.gov/cder/foi/label/20 09/019537s69,19847s43,19857s50,20780s27lbl.pdf. Accessed 6 May 2009.
15. Anquetin G, Greiner J, Mahmoud N, Santillana HM, Gozalbes R, Farhati K, et al. Design, synthesis and activity against Toxoplasma gondii, Plasmodium spp., and Mycobacterium tuberculosis of new 6-fuoroquinolones. Eur J Med Chem 2006;41:1478-1493 (Pubitemid 44880496)
16. Farhi D, Dupin N. Te rise of fuoroquinolone-resistant Neisseria gonorrhoeae. Swiss Med Wkly 2008;138:223-224
17. 18F] Ciprofoxacin, a new positron emission tomography tracer for noninvasive assessment of the tissue distribution and pharmacokinetics of ciprofoxacin in humans. Antimicrob Agents Chemother 2004;48:3850-3857 (Pubitemid 39304614)
18. Kubin R. Safety and efcacy of ciprofoxacin in paedatric patients\review. Infection 1993;21:413-421
19. Wimer SM, Schoonover L, Garrison MW. Levofoxacin: a therapeutic review. Clin Ter 1998;20:1049-1068
20. Antonio DD, Piccolomini R, Iacone A, Fioritoni G, Parruti G, Betti S, et al. Comparison of ciprofoxacin, ofoxacin and pefoxacin for the prevention of the bacterial infection in neutropenic patients with haematological malignancies. J Antimicrob Chemother 1994;33:837-844 (Pubitemid 24149819)
21. Yamane N, Jones RN, Frei R, Hoban DJ, Pignatari AC, Marco F. Levofoxacin in vitro activity: results from an international comparative study with ofoxacin and ciprofoxacin. J Chemother 1994;6:83-91. (Pubitemid 24208207)
22. Joseph E, Dohar MD, Wall M, Peter S, Roland PS, Dupre SJ, et al. Topical ciprofoxacin/dexamethasone found superior to oral amoxicillin/clavulanic acid in acute otitis media with otorrhea. Otolaryngol Head Neck Surg 2005;133:127.
23. Brunner H, Zeiler HJ. Oral ciprofoxacin treatment for salmonella typhimurium infection of normal and immunocompromised mice. Antimicrob Agents Chemother 1988;32:57-62. (Pubitemid 18025677)
24. Herold C, Ocker M, Ganslmayer M, Gerauer H, Hahn EG, Schuppan D. Ciprofoxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells. Br J Cancer 2002;86:443-448 (Pubitemid 34185131)
25. 2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res 2000;6:891-900.
26. Aranha O, Grignon R, Fernandes N, Mcdonnell TJ, Wood DP, Sarkar FH. Suppression of human prostate cancer cell growth by ciprofoxacin is associated with cell cycle arrest and apoptosis. Int J Oncol 2003;22:787-794
27. Pinto AC, Moreira JN, Simoes S. Ciprofoxacin sensitizes hormone-refractory prostate cancer cell lines to doxorubicin and docetaxel treatment on a schedule-dependent manner. Cancer Chemother Pharmacol 2009;64:445-454
28. Bourikas LA, Kolios G, Valatas V, Notas G, Drygiannakis I, Pelagiadis I, et al. Ciprofoxacin decreases survival in HT-29 cells via the induction of TGF-beta1 secretion and enhances the anti-proliferative efect of 5-fuorouracil. Br J Pharmacol 2009;157:362-370
29. Ibukun EA, Eyitayo OA, Nwaka DUC, Aminat OA, Aderemi TA, Oludare FA, et al. Emergence of cross-resistance to fuoroquinolones in Gram-negative isolates from cancer infections in a tertiary hospital in Nigeria. J Am Sci 2008;4:14-20.
30. Dekker AW, Rosenberg AM, Verhoef J. Infection prophylaxis in acute leukaemia: a comparison of ciprofoxacin with trimethoprim-sulfamethoxazole and colistin. Anna Intern Med 1987;106:7-11. (Pubitemid 17228301)
31. Haron E, Rolston KVI, Cunningham C, Holmes F, Umsawasdi T, Bodey GP. Oral ciprofoxacin therapy for infections in cancer patients. J Antimicrob Chemother 1989;24:955-962 (Pubitemid 20040556)
32. Balkhy HH, Memish ZA, Shibl A, Elbashier A, Osoba A. In vitro activity of quinolones against S. pneumoniae, H. infuenzae and M. catarrhalis in Saudi Arabia. East Mediterr Health J 2005;11:36-44. (Pubitemid 43308564)
33. Aydemir S, Tunger A, Cilli F. In vitro activity of fuoroquinolones against common respiratory pathogens. West Indian Med J 2006;55:9-12.
34. Cassell GH, Mekalanos J. Development of antimicrobial agent in the era of new and reemerging infectious diseases and increasing antibiotic resistance. JAMA 2001;285:601-605 (Pubitemid 32656331)
35. Rubin J, Walker RD, Blickenstaf K, Jones SB, Zhao S. Antimicrobial resistance and genetic characterization of fuoroquinolone resistance of Pseudomonas aeruginosa isolated from canine infections. Vet Microbiol 2008;131:164-172
36. Cozzarelli NR. DNA gyrase and the supercoiling of DNA. Science 1980;207:953-960
37. Schmidt FJ, Hofmann B, Hansen B, Scheuring S, Luckefahr M, Klootwijk M, et al. Relationship between ciprofoxacin, ofoxacin, levofoxacin, sparfoxacin and moxifoxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 1998;41: 481-484
38. Walters JD, Zhang F, Nakkula RJ. Mechanism of fuoroquinolone transport by human neutrophils. Antimicrob Agents Chemother 1999;43:2710-2715 (Pubitemid 29519552)
39. Shaharyar M, Ashraf Ali EM, Abdullah MM. Synthesis and antiproliferative activity of 1-[(sub)]-6-fuoro-3-[(sub)]-1,3,4-oxadiazol-2-yl-7-piperazino-1,4- dihydro-4-quinolone derivatives. Med Chem Res 2007;16:292-299 (Pubitemid 350215073)
40. Vila J, Sanchez-Cespedes J, Sierra JM, Piqueras M, Nicolas E, Freixas J, et al. Antibacterial evaluation of a collection of norfoxacin and ciprofoxacin derivatives against multiresistant bacteria. Int J Antimicrob Agents 2006;28:19-24. (Pubitemid 43914395)
41. Foroumadi A, Emami S, Mehni M, Moshaf MH, Shafee A. Synthesis and antibacterial activity of N-[2-(5-bromothiophen-2-yl)-2-oxoethyl] and N-[2-(5-bromothiophen-2-yl)-2-oximinoethyl] derivatives of piperazinyl quinolones. Bioorg Med Chem Lett 2005;15:4536-4539 (Pubitemid 41253889)
42. Foroumadi A, Emami S, Hassanzadeh A, Rajaee M, Sokhanvar K, Moshaf MH, et al. Synthesis and antibacterial activity of N-(5-benzylthio-1,3,4-thiadiazol-2- yl) and N-(5-benzylsulfonyl-1,3,4-thiadiazol-2-yl)piperazinyl quinolone derivatives. Bioorg Med Chem Lett 2005;15:4488-4492
43. Foroumadi A, Oboudiat M, Emami S, Karimollah A, Saghaee L, Moshaf MH, et al. Synthesis and antibacterial activity of N-[2-[5-(methylthio)thiophen-2-yl]- 2-oxoethyl] and N-[2-[5-(methylthio) thiophen-2-yl]-2-(oxoimino)ethyl] piperazinyl quinolone derivatives. Bioorg Med Chem 2006;14:3421-3427
44. Foroumadi A, Ghodsi S, Emami S, Najjari S, Samadi N, Faramarzi MA, et al. Synthesis and antibacterial activity of new fuoroquinolones containing a substituted N-(phenethyl)piperazine moiety. Bioorg Med Chem Lett 2006;16:3499-3503 (Pubitemid 43777121)
45. Talath S, Gadad AK. Synthesis, antibacterial and antitubercular activities of some 7-[4-(5-amino-1,3,4 thiadiazole-2-sulfonyl)-piperazin-1-yl] fuoroquinolone derivatives. Eur J Med Chem 2006;41:918-924
46. Nieto MJ, Alovero FL, Manzo RH, Maria RM. Benzenesulfonamide analogs of fuoroquinolones: antibacterial activity and QSAR studies. Eur J Med Chem 2005;40:361-369
47. Sriram D, Yogeeswari P, Basha JS, Radhab DR, Nagaraja V. Synthesis and antimycobacterial evaluation of various 7-substituted ciprofoxacin derivatives. Bioorg Med Chem 2005;13:5774-5778 (Pubitemid 41247759)
48. Kerns RJ, Rybak MJ, Glenn WK, Vaka F, Cha R, Grucz RG, et al. Piperazinyl-linked fuoroquinolone dimmers possessing potent antibacterial activity against drug resistant strains of Staphylococcus aureus. Bioorg Med Chem Lett 2003;13:1745-1749 (Pubitemid 36561156)
49. Imramovsky A, Polanc S, Vinsova J, Kocevar M, Jampilek J, Reckova Z, et al. A new modifcation of antitubercular active molecules. Bioorg Med Chem 2007;15:2551-2559 (Pubitemid 46367712)
50. Srivastava BK, Solanki M, Mishra B, Soni R, Jayadev S, Valani D, et al. Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c] pyridine quinolones. Bioorg Med Chem Lett 2007;17:1924-1929. (Pubitemid 46394536)
51. German N, Wei P, Kaatz GW, Kerns RJ. Synthesis and evaluation of fuoroquinolone derivatives as substrate-based inhibitors of bacterial efux pump. Eur J Med Chem 2008;43:2453-2463
52. Al-Soud Y, Al-Masoudi NA. A new class of dihaloquinolones bearing N-aldehydoglycosylhydrazides, mercapto-1,2,4-triazole, oxadiazoline and α-amino ester precursors: synthesis and antimicrobial activity. J Braz Chem Soc 2003;14:790-796 (Pubitemid 37414560)
53. Zhao YL, Chen YL, Sheu JY, Chen IL, Wang TC, Tzeng CC. Synthesis and antimycobacterial evaluation of certain fuoroquinolone derivatives. Bioorg Med Chem 2005;13:3921-3926 (Pubitemid 40725025)
54. Yadav P, Joshi YC. Synthesis and spectral studies of novel ciprofoxacin derivatives. Bull Chem Soc Ethiop 2008;22:459-464
55. Sriram D, Yogeeswari P, Senchani G, Banerjee D. Newer tetracycline derivatives: synthesis, anti-HIV, antimycobacterial activities and inhibition of HIV-1 integrase. Bioorg Med Chem Lett 2007;17:2372-2375 (Pubitemid 46484288)
56. Ye FQ, Ding YM, Chen L, Ye S, Chen ZX. Synthesis and antibacterial activity of ciprofoxacin derivatives. Acta Pharmaceutica Sinica 2005;40:132-135. (Pubitemid 40445188)
57. Bani ZT, Kujund N, Kraja MB, Njevac AV, Prodi BK. Molecular structures of new ciprofoxacin derivatives. Journal of Molecular Structure 2002;611:73-81.
58. Hu GQ, Wu XK, Wang X, Zhang ZQ, Xie SQ, Huang WL, Zhang HB. Synthesis and antitumor activity of C-3 heterocyclic-substituted fuoroquinolone derivatives (I): ciprofoxacin aminothiodiazole schif-bases. Acta Pharmaceut Sin 2008;43:1112-1115
59. Vazquez JL, Merino S, Domenech O, Berlanga M, Vinas M, Montero MT, et al. Determination of the partition coefcients of a homologous series of ciprofoxacin: infuence of the N-4 piperazinyl alkylation on the antimicrobial activity. Int J Pharm 2001;220:53-62. (Pubitemid 32476841)
60. Azema J, Guidetti B, Dewelle J, Le Calve B, Mijatovic T, Korolyov A, et al. 7-((4-Substituted)piperazin-1-yl) derivatives of ciprofoxacin: synthesis and in vitro biological evaluation as potential antitumor agents. Bioorg Med Chem 2009;17:5396-5407
61. Siddiqui R, Najma S, Khalid MK, Nosheen A, Muhammad A, Saeed A. Efects of skeletal modifcations of ciprofoxacin on antibacterial, antifungal and cytotoxic activities. J Chin Clin Med 2007;2:188-195
62. Sharma PC, Jain S. Synthesis and antibacterial activity of certain novel 1-cyclopropyl-6-fuoro-1,4-dihydro-7-4-substituted-piperazin-1-yl-4-oxoquinoline- 3-carboxylates. Acta Pharm Sci 2008;50: 35-40.
63. Hirai K, Aoyama H, Irikura T, Iyobe S, Mitsuhashi S. Diferences in susceptibility to quinolones of outer mermbrane mutants of Salmonella typhimurium and Escherichia coli. Antimicrob Agents Chemother 1986;29:535-538 (Pubitemid 16143272)
64. Melo MJP, Varanda FR, Dohrn R, Marrucho IM. Solubility of ciprofoxacin and moxifoxacin in diferent solvents: the efect of the HCl group. Enpromer 2005;1-5. http://www.enpromer2005.eq.ufrj.br/nukleo/pdfs/0984-solubility-of- antibiotics.pdf. Accessed 26 June 2009.
65. Varanda F, De Melo MJP, Caco AI, Dohrn R, Makrydaki FA, Voutsas E, et al. Solubility of antibiotics in diferent solvents. 1. Hydrochloride forms of tetracycline, moxifoxacin, and ciprofoxacin. Ind Eng Chem Res 2006;45:6368-6374
66. Lavda M, Clausnitzer CE, Walters JD. Distribution of systemic ciprofoxacin and doxycycline to gingival and gingival crevicular fuid. J Periodontol 2004;75:1663-1667 (Pubitemid 40260018)
67. Tyczkowska K, Hedeen KM, Aucoin DP, Aronson AL. High-performance liquid chromatographic method for the simultaneous determination of enrofoxacin and its primary metabolite ciprofoxacin in canine serum and prostatic tissue. J Chromatogr 1989;493:337-346 (Pubitemid 19220072)
68. Samanidou VF, Demetriou CE, Papadoyannis IN. Direct determination of four fuoroquinolones, enoxacin, norfoxacin, ofoxacin, and ciprofoxacin, in pharmaceuticals and blood serum by HPLC. Anal Bioanal Chem 2003;375:623-629
69. Pham HH, Luo P, Genin F, Dash AK. Synthesis and characterization of hydroxyapatite-ciprofoxacin delivery systems by precipitation and spray drying technique. AAPS PharmSciTech 2002;3:1-9. (Pubitemid 41086089)
70. Krzek J, Hubicka U, Szczepaniczyk J. High-performance thin-layer chromatography with densitometry for the determination of ciprofoxacin and impurities in drugs. J AOAC Int 2005;88:1530-1536 (Pubitemid 41561919)
71. Han-Wen S, Li-Qing L, Xue-Yan C, Hong-Mei S, Yun-Kai L. Determination of norfoxacin by fow injection analysis with chemiluminescence detection. Can J Anal Sci Spectrosc 2006;51:100-107
72. Duan J, Yuan Z. Development of an indirect competitive ELISA for ciprofoxacin residues in food animal edible tissues. J Agric Food Chem 2001;49:1087-1089 (Pubitemid 32884914)
73. Heinz-Georg W, Stadler M, Hans-Volker T, Dalhof A, Karl W. Degradation of ciprofoxacin by basidiomycetes and identifcation of metabolites generated by the brown rot fungus Gloeophyllum striatum. Appl Environ Microbiol 1999;65:1556-1563 (Pubitemid 29173684)
74. Yan H, Tian M, Row KH. Determination of enrofoxacin and ciprofoxacin in milk using molecularly imprinted solid-phase extraction. J Sep Sci 2008;31:3015-3020
75. Michalska K, Pajchel G, Tyski S. Determination of ciprofoxacin and its impurities by capillary zone electrophoresis. J Chromatogr A 2004;1051:267-272 (Pubitemid 39298853)
76. Kassab NM, Singh AK, Kedor-Hackmam ERM, Santoro MIRM. Quantitative determination of ciprofoxacin and norfoxacin in pharmaceutical preparations by high performance liquid chromatography. Braz J Pharm Sci 2005;41:507-513
77. Xiao JB, Yang CS, Ren FL, Jiang XY, Xu M. Rapid determination of ciprofoxacin lactate in drugs by the Rayleigh light scattering technique. Meas Sci Technol 2007;18:859-866 (Pubitemid 46603750)
78. Ovando HG, Gorla1 N, Weyers A, Ugnia L, Magnoli A. Simultaneous quantifcation of ciprofoxacin, enrofoxacin and balofoxacin in broiler chicken muscle. Arch Med Vet 2004;1:93-98 (Pubitemid 39118873)
79. Joos B, Ledergerber B, Flepp M, Bettex JD, Luthy R, Siegenthaler W. Comparision of high-pressure liquid chromatography and bioassay for determination of ciprofoxacin in serum and urine. Antimicrob Agents Chemother 1985;27:353-356 (Pubitemid 15144699)
80. Nix DE, De Vito JM, Schentag JJ. Liquid-chromatographic determination of ciprofoxacin in serum and urine. Clin Chem 1985;31:684-686 (Pubitemid 16185943)
81. Martin BS, Cornejo J, Iraguen D, Hidalgo H, Anadon A. Depletion study of enrofoxacin and its metabolite ciprofoxacin in edible tissues and feathers of white leghorn hens by liquid chromatography coupled with tandem mass spectrometry. J Food Protect 2007;70:1952-1957 (Pubitemid 47237420)
82. Egle JL. Principles of Pharmacology: Basic Concepts and Clinical Applications. New York: Chapman & Hall, 1996:1339-1350
83. Leone M, Sampol-Manos E, Santelli D, Grabowski S, Alliez B, Durand A, et al. Brain tissue penetration of ciprofoxacin following a single intravenous dose. J Antimicrob Chemother 2002;50:607-609 (Pubitemid 35214805)
84. Lipman J, Allworth A, Wallis SC. Cerebrospinal fuid penetration of high doses of intravenous ciprofoxacin in meningitis. Clin Infect Dis 2000;31:1131-1133 (Pubitemid 32295439)
85. Blondeau JM. Expanded activity and utility of the new fuoroquinolones: a review. Clin Ter 1999;21:3-39.
86. Brunton LL, Lazo JS, Parker KL. Goodman and Gilman's the Pharmacological Basis of Terapeutics. New York: McGraw-Hill, 2006:1111-1126
87. Sharma PC, Saneja A, Jain S. Norfoxacin: a therapeutic review. Int J Chem Sci 2008;6:1702-1713
88. Cheng D, Xu WR, Liu CX. Relationship of quantitative structure and pharmacokinetics in fuoroquinolone antibacterials. World J Gastroenterol 2007;13:2496-2503 (Pubitemid 46929507)
89. Scholar EM. Fluoroquinolones: past, present and future of a novel group of antibacterials. Am J Pharm Educ 2003;66:164-172
90. Polachek H, Holcberg G, Sapir G, Tsadkin-Tamir M, Polachek J, Katz M, et al. Transfer of ciprofoxacin, ofoxacin and levofoxacin across the perfused human placenta in vitro. Eur J Obstet Gynecol Reprod Biol 2005;122:61-65 (Pubitemid 41265682)
91. Brunner M, Stab H, Moller JG, Schrolnberger C, Erovic B, Hollenstein U, et al. Target site concentrations of ciprofoxacin after single intravenous and oral doses. Antimicrob Agents Chemother 2002;46:3724-3730 (Pubitemid 35403243)
92. Wolfson JS, Hooper DC. Pharmacokinetics of quinolones: newer aspects. Eur J Clin Microbiol Infect Dis 1991;10:267-274
93. Apley MD, Upson DW. Lung tissue concentrations and plasma pharmacokinetics of danofoxacin in calves with acute pneumonia. Am J Vet Res 1993;54:937-943
94. Sarkozy G. Quinolones: a class of antimicrobial agents. Vet Med Czech 2001;46:257-274 (Pubitemid 33671418)
95. Ho PL, Que TL, Tsang DNC, Ng TK, Chow KH, Seto WH. Emergence of fuoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother 1999;43:1310-1313 (Pubitemid 29214773)
96. Chen DK, McGeer A, De Azaevedo JC, Low DE. Fluoroquinolone resistance in Streptococcus pneumoniae. N Engl J Med 1999;341:233-239
97. Liu L, Guo K, Lu J, Venkatraman SS, Luo D, Chey NK, et al. Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier. Biomaterials 2008;29:1509-1517
98. Brook I. Te prophylaxis and treatment of anthrax. J Antimicrob Agents 2002;20:320-325
99. Kepa L, Oczko-Grzesik B, Stolarz W, Sobala SB. Drug-induced aseptic meningitis in suspected central nervous system infections. J Clin Neurosci 2005;12:562-564 (Pubitemid 41044200)
100. Mao Z, Ma L, Gao C, Shen J. Preformed microcapsules for loading and sustained release of ciprofoxacin hydrochloride. J Control Release 2005;104:193-202. (Pubitemid 40615246)
101. Oliphant CM, Green GM. Quinolones: a comprehensive review. Am Fam Physician 2002;65:455-464
102. Feliciano J, Teper E, Ferrandino M, Macchia RJ, Blank W, Grunberger I, et al. Te incidence of fuoroquinolone resistant infections after prostate biopsy are fuoroquinolones still efective prophylaxis. J Urol 2008;179:952-5; discussion 955.
103. Gottberg AV, Klugman KP, Cohen C, Wolter N, De Gouveia L, Du Plessi M, et al. Emergence of levofoxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study. Lancet 2008;371:1108-1113
104. Dollery C. Terapeutic Drugs. Edinburgh: Churchill Livingstone, 1999:N137-40.
105. Efthymiopoulos C, Blum B, Maroli A, Bramer SL. Teophylline and warfarin interaction studies with grepafoxacin. Clin Pharmacokinet 1997;33:39-46. (Pubitemid 28014530)
106. Neu HC, Kumada T, Chin NX, Mandell W. Te post-antimicrobial suppressive efect of quinolone agents. Drugs Exp Clin Res 1987;13:63-67 (Pubitemid 17049978)
107. Lubasch A, Keller I, Borner K, Koeppe P, Lode H. Comparative pharmacokinetics of ciprofoxacin, gatifoxacin, grepafoxacin, levofoxacin, trovafoxacin, and moxifoxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 2000;44:2600-2603
108. Boy D, Well M, Kinzig SM, Sorgel F, Ankel FD, Naber KG. Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifoxacin (400 mg) versus ciprofoxacin (500 mg) in healthy volunteers after a single oral dose. Int J Antimicrob Agents 2004;23:6-16. (Pubitemid 38376044)
109. Drug card for ciprofoxacin (DB00537). Drug bank 19 Feb 2009. http://www.drugbank.ca/drugs/DB00537. Accessed 6 May 2009.
110. Karachalios GN, Zografos G, Patrikakos V, Nassopoulou D, Kehagioglou K. Biliary tract infections treated with ciprofoxacin. Infection 2005;21: 262-264
111. Launay E, Joram N, Jacqueline C, Miegeville A F, Caillon J, Potel G, et al. Efcacy of ciprofoxacin in an experimental model of Escherichia coli chorioamnionitis in rabbits. Antimicrob Agents Chemother 2009;53:1624-1627
112. Capoor MR, Rawat D, Nair D, Hasan AS, Deb M, Aggarwal P, et al. In-vitro activity of azithromycin, newer quinolones and cephalosporins in ciprofoxacin-resistant Salmonella causing enteric fever. J Med Microb 2007;56:1490-1494 (Pubitemid 350175075)
113. Wexler HM, Molitoris E, Molitoris D, Finegold SM. In vitro activity of levofoxacin against a selected group of anaerobic bacteria isolated from skin and soft tissue infections. Antimicrob Agents Chemother 1998;42:984-986 (Pubitemid 28216400)
114. Raina R, Prawez S, Dimitrova DJ, Pankaj NK, Verma PK. Disposition kinetics and urinary excretion of ciprofoxacin in goats following single intravenous administration. J Vet Sci 2008;9:241-245
115. Fontan MP, Rosales M, Fernandez F, Moncalian J, Fernandez CR, Alonso A, et al. Ciprofoxacin in the treatment of Gram positive bacterial peritonitis in patients undergoing CAPD. Perit Dial Int 1991;11:233-236
116. Zeiler HJ, Grohe K. Te in vitro and in vivo activity of ciprofoxacin. Eur J Clin Microbiol 1984;3:393-443
117. Vali A, Faghihi G, Zaghian N, Koosha M. Te efcacy of topical solution of 0.3% ciprofoxacin in treatment of mild to moderate acne vulgaris. Iranian Red Cresc Med J 2009;11:23-27.
118. Bakker-Woudenberg IAJM, Ten Kate MT, Guo L, Working P, Mouyon JW. Improved efcacy of ciprofoxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats. Antimicrob Agents Chemother 2001;45:1487-1492 (Pubitemid 32374122)
119. Sheng WH, Wang JT, Chen YC, Chang SC, Luh KT. In vitro activity of moxifoxacin against common clinical bacterial isolates in Taiwan. J Microbiol Immunol Infect 2001;34:178-184